<PAPER><mode2 name='PMC4255993' hasDoc='yes' version='597'></mode2><article xmlns:mml='http://www.w3.org/1998/Math/MathML' xmlns:xlink='http://www.w3.org/1999/xlink' article-type='research-article'><front><journal-meta><journal-id journal-id-type='nlm-ta'>Dement Geriatr Cogn Dis Extra</journal-id><journal-id journal-id-type='iso-abbrev'>Dement Geriatr Cogn Dis Extra</journal-id><journal-id journal-id-type='publisher-id'>DEE</journal-id><journal-title-group><journal-title>Dementia and Geriatric Cognitive Disorders EXTRA</journal-title></journal-title-group><issn pub-type='ppub'>1664-5464</issn><issn pub-type='epub'>1664-5464</issn><publisher><publisher-name>S. Karger AG</publisher-name><publisher-loc>Allschwilerstrasse 10, P.O. Box · Postfach · Case postale, CH–4009, Basel, Switzerland · Schweiz · Suisse, Phone: +41 61 306 11 11, Fax: +41 61 306 12 34, karger@karger.ch</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type='pmcid'>4255993</article-id><article-id pub-id-type='doi'>10.1159/000363622</article-id><article-id pub-id-type='publisher-id'>dee-0004-0395</article-id><article-categories><subj-group subj-group-type='heading'><subject>Original Research Article</subject></subj-group></article-categories><title-group><article-title><s sid='1'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Goa1' type='Goa'></CoreSc1>Effects of a Rivastigmine Patch on Self-Care Activities in Patients with Alzheimer's Disease plus Cerebrovascular Disease</s></article-title></title-group><contrib-group><contrib contrib-type='author'><name><surname>Kim</surname><given-names>Yong Kyun</given-names></name><xref rid='aff1' ref-type='aff'>a</xref><xref rid='cor1' ref-type='corresp'>*</xref></contrib><contrib contrib-type='author'><name><surname>Lim</surname><given-names>Kil-Byung</given-names></name><xref rid='aff2' ref-type='aff'>b</xref></contrib><contrib contrib-type='author'><name><surname>Lee</surname><given-names>Sang Chul</given-names></name><xref rid='aff3' ref-type='aff'>c</xref></contrib><contrib contrib-type='author'><name><surname>Park</surname><given-names>Jin-Woo</given-names></name><xref rid='aff4' ref-type='aff'>d</xref></contrib><contrib contrib-type='author'><name><surname>Lee</surname><given-names>Hong-Jae</given-names></name><xref rid='aff2' ref-type='aff'>b</xref></contrib><contrib contrib-type='author'><name><surname>Kwon</surname><given-names>Bum Sun</given-names></name><xref rid='aff4' ref-type='aff'>d</xref></contrib><contrib contrib-type='author'><name><surname>Lee</surname><given-names>Ho Jun</given-names></name><xref rid='aff4' ref-type='aff'>d</xref></contrib></contrib-group><aff id='aff1'><sup>a</sup>Department of Physical Medicine and Rehabilitation, Myongji Hospital, Kwandong University College of Medicine, Goyang, South Korea</aff><aff id='aff2'><sup>b</sup>Department of Physical Medicine and Rehabilitation, Ilsan Paik Hospital, Inje University, Gimhae-si, South Korea</aff><aff id='aff3'><sup>c</sup>Department of Physical Medicine and Rehabilitation, Yonsei University College of Medicine, Seoul, South Korea</aff><aff id='aff4'><sup>d</sup>Department of Physical Medicine and Rehabilitation, Dongguk University College of Medicine, Gyeongju-si, South Korea</aff><author-notes><corresp id='cor1'>*Yong Kyun Kim, 697-24 Hwajung, Dukyang, Koyang, Kyunggi (South Korea), E-Mail <email>yongkyunk@gmail.com</email></corresp></author-notes><pub-date pub-type='collection'><season>Sep-Dec</season><year>2014</year></pub-date><pub-date pub-type='epub'><day>29</day><month>10</month><year>2014</year></pub-date><pub-date pub-type='pmc-release'><day>29</day><month>10</month><year>2014</year></pub-date><volume>4</volume><issue>3</issue><fpage>395</fpage><lpage>401</lpage><permissions><copyright-statement>Copyright © 2014 by S. Karger AG, Basel</copyright-statement><copyright-year>2014</copyright-year><license license-type='open-access' xlink:href='http://creativecommons.org/licenses/by-nc/3.0/'><license-p>This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Users may download, print and share this work on the Internet for noncommercial purposes only, provided the original work is properly cited, and a link to the original work on http://www.karger.com and the terms of this license are included in any shared versions.</license-p></license></permissions><abstract><sec><title>Background/Aims</title><p><s sid='2'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>In dementia patients, a deficit in activities of daily living (ADL) is one of the main problems.</s><s sid='3'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Goa1' type='Goa'></CoreSc1><CoreSc2 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc2> Our objective was to assess ADL using the Korean Modified Barthel Index (K-MBI) in patients with Alzheimer's disease (AD) plus cerebrovascular disease (CVD) treated with a rivastigmine patch for 24 weeks in an open-label, observational study.</s></p></sec><sec><title>Methods</title><p><s sid='4'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1>29 patients were enrolled who met the National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS/ ANDRA) criteria and had a score of 10-26 on the Korean version of the Mini-Mental State Examination (K-MMSE).</s><s sid='5'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> After the rivastigmine patch had been applied for 24 weeks, changes in self-care activities were assessed using the K-MBI.</s></p></sec><sec><title>Results</title><p><s sid='6'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1>The average age of the patients was 62.8 years, and they had an average K-MMSE score of 16.2.</s><s sid='7'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Patients showed a mean improvement of 21.9 points, as compared with the baseline K-MBI score of 30.3 (p &lt; 0.05).</s><s sid='8'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Significantly better outcomes were seen in secondary outcome variables, for example the K-MMSE and backward digit span.</s><s sid='9'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> The most frequent adverse events were skin problems, such as itching sensation (10%).</s></p></sec><sec><title>Conclusion</title><p><s sid='10'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1>In this multicenter, open-label, observational study, the rivastigmine patch was associated with improvements in ADL in patients with AD plus CVD.</s></p></sec></abstract><kwd-group><title>Key Words</title><kwd>Alzheimer's disease with cerebrovascular disease</kwd><kwd>Rivastigmine patch</kwd><kwd>Activities of daily living</kwd></kwd-group><counts><fig-count count='3'></fig-count><table-count count='1'></table-count><ref-count count='22'></ref-count><page-count count='7'></page-count></counts></article-meta></front><body><sec sec-type='intro' id='sec1_1'><title>Introduction</title><p><s sid='11'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Alzheimer's disease (AD) is clinically defined as a decline in cognition, a deterioration in the ability to perform activities of daily living (ADL), and having behavioral problems [<xref rid='B1' ref-type='bibr'>1</xref>,<xref rid='B2' ref-type='bibr'>2</xref>,<xref rid='B3' ref-type='bibr'>3</xref>].</s><s sid='12'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> There is increasing evidence that AD frequently coexists with significant cerebrovascular disease (CVD) pathology [<xref rid='B4' ref-type='bibr'>4</xref>].</s><s sid='13'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Clinically, AD with CVD coexists in many dementia patients [<xref rid='B5' ref-type='bibr'>5</xref>].</s></p><p><s sid='14'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Patients with AD plus CVD need assistance in all aspects of daily living because of a cognitive decline, even though they have good muscle strength, coordination, and balance.</s><s sid='15'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The level of dependency of the patients is a measurement reflecting the level of severity of the disease which can be seen in ADL [<xref rid='B6' ref-type='bibr'>6</xref>].</s></p><p><s sid='16'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>The current standard therapy for mild-to-moderate AD with CVD is cholinesterase inhibitors [<xref rid='B7' ref-type='bibr'>7</xref>,<xref rid='B8' ref-type='bibr'>8</xref>].</s><s sid='17'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Rivastigmine patch is one of the cholinesterase inhibitors.</s><s sid='18'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> In 2007, a transdermal patch formulation of rivastigmine became available in the United States for the treatment of mild-to-moderate AD [<xref rid='B9' ref-type='bibr'>9</xref>,<xref rid='B10' ref-type='bibr'>10</xref>].</s><s sid='19'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Its efficacy and safety are already known [<xref rid='B11' ref-type='bibr'>11</xref>,<xref rid='B12' ref-type='bibr'>12</xref>].</s><s sid='20'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Improvement in cognition could secondarily lead to improvement in ADL.</s><s sid='21'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Mot1' type='Mot'></CoreSc1> However, previous reports do not show consistent results [<xref rid='B5' ref-type='bibr'>5</xref>], which might be due to a low sensitivity to assess ADL [<xref rid='B13' ref-type='bibr'>13</xref>].</s></p><p><s sid='22'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Goa1' type='Goa'></CoreSc1>Our objective was to assess ADL using the Korean Modified Barthel Index (K-MBI) in patients with AD plus CVD treated with a rivastigmine patch for 24 weeks.</s></p></sec><sec sec-type='methods' id='sec1_2'><title>Methods</title><sec id='sec2_1'><title>Subjects</title><p><s sid='23'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>This open-label, single-arm study assesses the efficacy of a rivastigmine patch on ADL in patients with AD plus CVD using the K-MBI.</s></p><p><s sid='24'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1>Patients with the following inclusion criteria were enrolled in the study: male or female individuals with a diagnosis of possible AD plus CVD according to the National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) criteria [<xref rid='B14' ref-type='bibr'>14</xref>].</s><s sid='25'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1> Further inclusion criteria were subjects with a dementia onset after the age of 50 and a score of 10-26 on the Korean version of the Mini-Mental State Examination (K-MMSE).</s></p><p><s sid='26'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1>Patients were excluded from the study if they had other neurologic or psychiatric disorders (schizophrenia, severe major depression), and if they were suspected of having been addicted to drugs or alcohol for the past 10 years.</s><s sid='27'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Patients with hepatic, renal, pulmonary, or cardiovascular disorders, such as bradycardia (pulse rate &lt;50), sick sinus syndrome or any medical condition which would prevent them from completing the study, or patients who did not have the appropriate characteristics to be included in the study according to the investigator were excluded as well.</s></p><p><s sid='28'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>Fifty subjects were calculated on the basis of power calculation; the power was 80%, with an alpha value of 0.05, and the expected change in the values on the K-MBI after 24 weeks was 10 ± 5 in the pilot study.</s></p><p><s sid='29'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1>At the first visit, subjects went through history taking, physical examination, evaluation of ADL by the K-MBI, of cognition by the K-MMSE and of language by the Korean version of the Western Aphasia Battery.</s><s sid='30'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> After the subjects had decided to use the rivastigmine patch, those who agreed to give personal data on medical information were enrolled.</s><s sid='31'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Then, they were assigned to 5 cm<sup>2</sup> of rivastigmine patch (delivering 4.6 mg/24 h) for 4 weeks.</s><s sid='32'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> After this titration period, the side effects, if any at all, were reported.</s><s sid='33'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Thereafter, the subjects were treated with 10 cm<sup>2</sup> of rivastigmine patch (delivering 9.5 mg/24 h) for another 20 weeks.</s><s sid='34'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Therefore, the total duration of the study was 24 weeks.</s><s sid='35'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> After 24 weeks of applying a rivastigmine patch, ADL changes were reevaluated by using the K-MBI.</s></p></sec><sec id='sec2_2'><title>Outcome Measures</title><p><s sid='36'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>The primary scale used was the K-MBI.</s><s sid='37'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Each performance item is rated on this ordinal scale with a given number of points assigned to each level or ranking.</s><s sid='38'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The Barthel scale was introduced in 1965 and yields a score of 0-20.</s><s sid='39'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> It is composed of 10 categories, which are bowel control, bladder control, grooming, toileting, transfer, mobility, dressing, climbing stairs, bathing, and feeding.</s><s sid='40'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> The subjects were given a score for each category according to their independence level, where dependent = 0, needs some help = 1, and independent = 2.</s><s sid='41'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The K-MBI was developed in 2007.</s><s sid='42'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> It consists of personal hygiene, bathing, self-feeding, toileting, stair climbing, dressing, bowel control, bladder control, ambulation or wheelchair, and chair/bed transfer.</s><s sid='43'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> The subjects were given a score for each item according to the independence level, where dependent = 0, needs 75% assistance = 2, needs 50% assistance = 5, needs 25% assistance = 8, and independent = 10.</s><s sid='44'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The range of the score of the K-MBI is 0–100 with a higher score implying more independence in ADL.</s><s sid='45'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The K-MBI is a valid and reliable method for measuring the functional status of the elderly (validity = 0.94, reliability = 0.97, and interrater agreement in 10 items = 0.82–1.0).</s><s sid='46'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> It has been used in many clinical studies.</s><s sid='47'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The patients were evaluated at baseline and after 24 weeks.</s></p><p><s sid='48'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>Secondary variables were assessed using 5 categories.</s><s sid='49'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The K-MMSE evaluated cognitive function, the Korean version of the Western Aphasia Battery was used for language abilities, the forward and backward digit span for attention deficit, the Neuropsychiatric Inventory Questionnaire for abnormal behavior, and the Controlled Oral Word Association Test for frontal executive function.</s><s sid='50'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Those were evaluated at baseline and 24 weeks after applying the rivastigmine patch.</s></p></sec><sec id='sec2_3'><title>Statistical Analysis</title><p><s sid='51'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>After analyzing the results of the primary and secondary variables, we performed a paired t test to assess the differences in the primary or secondary variables between baseline and 24 weeks.</s><s sid='52'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The analysis was performed with SPSS 12.0 (Statistical Package for the Social Science).</s></p></sec></sec><sec sec-type='results' id='sec1_3'><title>Results</title><p><s sid='53'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1>Forty-seven patients with possible AD plus CVD were included in this study.</s><s sid='54'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Among those, 18 subjects were excluded.</s><s sid='55'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> The most frequent reason for discontinuation was loss to follow-up (n = 12, 25.5%).</s><s sid='56'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> Four subjects were discarded for complaining of itching sensation (8.5%) on the site of applying the transdermal patch.</s><s sid='57'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> One subject was excluded from this study due to an insurance issue because of an improvement in K-MMSE score.</s><s sid='58'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Unfortunately, 1 study could not be completed because the subject died.</s><s sid='59'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1> This leaves us with a total of 29 subjects who completed this study.</s></p><p><s sid='60'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1>The average age of the study group was 62.8 ± 11.4 years; 44.8% were women (table <xref rid='T1' ref-type='table'>1</xref>).</s><s sid='61'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> The baseline average K-MBI score was 30.3 points and the baseline mean MMSE score was 16.2 points.</s></p><p><s sid='62'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>A primary efficacy variable was the mean change in the K-MBI score at 24 weeks, compared with the baseline score, in patients with AD plus CVD.</s><s sid='63'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Patients treated with a rivastigmine patch showed a mean improvement of 21.9 points (p &lt; 0.05) (fig. <xref rid='F1' ref-type='fig'>1a</xref>).</s><s sid='64'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> On the subscale analysis of self-care activities, improvements were observed especially in eating, toileting, dressing, transfer, gait, bladder control, and bowel control (fig. <xref rid='F1' ref-type='fig'>1b</xref>).</s></p><p><s sid='65'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1>Significantly better outcomes were seen in secondary efficacy variables, for example, the K-MMSE and the backward digit span in the Seoul Neuropsychological Screening Battery.</s><s sid='66'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> The mean K-MMSE score increased by 3.7 points (p &lt; 0.05) (fig. <xref rid='F2' ref-type='fig'>2</xref>).</s><s sid='67'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> In the backward digit span test, the mean improvement was 0.9 points (p &lt; 0.05) (fig. <xref rid='F3' ref-type='fig'>3</xref>).</s></p><p><s sid='68'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1>The most frequent adverse events were skin problems, such as itching on the site where the rivastigmine patch had been applied (about 8.5% of patients).</s></p></sec><sec sec-type='discussion' id='sec1_4'><title>Discussion</title><p><s sid='69'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>The level of dependency in ADL of patients with AD plus CVD has an effect on the quality of life of both patients and caregivers [<xref rid='B1' ref-type='bibr'>1</xref>,<xref rid='B6' ref-type='bibr'>6</xref>,<xref rid='B15' ref-type='bibr'>15</xref>].</s><s sid='70'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> This study showed that rivastigmine patches have positive effects on the self-care activities assessed by the K-MBI in patients with AD plus CVD.</s><s sid='71'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> The result of the subscale analysis of the K-MBI scores, showing a beneficial effect of the rivastigmine patch on the bowel control, bladder control, and dressing in patients with AD plus CVD, was compatible with a recent study [<xref rid='B3' ref-type='bibr'>3</xref>].</s></p><p><s sid='72'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>In a previous study, ADL was assessed as a measure using the 23-item ADCS-ADL inventory [<xref rid='B16' ref-type='bibr'>16</xref>].</s><s sid='73'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The ADCS-ADL is a questionnaire with a possible score of 0-78.</s><s sid='74'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Although the ADCS-ADL has many items (e.g. eating, walking, toileting), each category was included in only 2-4 other questionnaires for assessing ADL impairment levels.</s><s sid='75'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> In this study, we chose to use the K-MBI to evaluate ADL.</s><s sid='76'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The K-MBI has 10 items and each category has 5 levels of assistance: ‘unable to perform a task’, ‘maximal assistance’, ‘moderate assistance’, ‘minimal assistance’, and ‘full independent’.</s><s sid='77'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Thus, this evaluation tool is more sensitive for the assessment of ADL in patients with AD plus CVD.</s></p><p><s sid='78'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1>With respect to secondary outcome measures, at week 24, patients treated with the rivastigmine patch showed improvement in K-MMSE scores.</s><s sid='79'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> These data are similar to those in a previous study [<xref rid='B17' ref-type='bibr'>17</xref>].</s><s sid='80'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Among the cognitive domains of the K-MMSE, improvements were observed in the attention and visuospatial function domain.</s><s sid='81'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> This finding might be associated with a significant improvement in the backward digit span test of the Seoul Neuropsychological Screening Battery after 24 weeks of rivastigmine patch treatment.</s><s sid='82'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> We report that the rivastigmine patch might be working more effectively on the visuospatial function in AD patients with CVD.</s><s sid='83'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Hyp1' type='Hyp'></CoreSc1> A possible explanation for this is that the visuospatial function is related to the posterior parietal cortex of the right hemisphere of the brain.</s><s sid='84'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Hyp1' type='Hyp'></CoreSc1> This area has a lot of connections to the subcortical area such as basal ganglia, thalamus, and the limbic system.</s><s sid='85'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Hyp1' type='Hyp'></CoreSc1> Therefore, rivastigmine treatment might lead to a more efficient connection between the right parietal cortex and the subcortical area.</s><s sid='86'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> This interesting finding is compatible with the results of a recent study showing that rivastigmine treatment may be useful to accelerate the recovery of unilateral spatial neglect [<xref rid='B18' ref-type='bibr'>18</xref>].</s></p><p><s sid='87'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Previous studies reported placebo or untreated mean declines on the MMSE of approximately 2-3.5 points after 1 year, and of approximately 5.5-6.5 points after 2 years in patients with baseline MMSE scores of 10-26 [<xref rid='B19' ref-type='bibr'>19</xref>,<xref rid='B20' ref-type='bibr'>20</xref>].</s><s sid='88'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Also, annual placebo declines of approximately 11.5 points on the ADCS-ADL have been reported [<xref rid='B21' ref-type='bibr'>21</xref>].</s><s sid='89'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> In our study, patients treated with the rivastigmine patch showed improvement in the K-MMSE and K-MBI scores at 24 weeks of approximately 4 and 22 points on average, respectively.</s><s sid='90'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Hyp1' type='Hyp'></CoreSc1> One of the possible reasons for this might be the fact that most of our patients were at 4 months after stroke at the time of enrollment in this study.</s></p><p><s sid='91'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1>About 8.5% of the study population discontinued the trial because of application site reactions, such as itching sensation or redness.</s><s sid='92'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> These findings were consistent with a previous 6-month placebo-controlled trial [<xref rid='B22' ref-type='bibr'>22</xref>].</s><s sid='93'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> However, gastrointestinal symptoms such as nausea, vomiting, and diarrhea were rare.</s></p><p><s sid='94'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>Several potential limitations of this study include: the open-label nature of the observational study design or the lack of direct concurrent comparison with a placebo control group, the relatively small sample size, and the fact that it was not a double-blind randomized controlled study.</s></p><p><s sid='95'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Mot1' type='Mot'></CoreSc1>Therefore, in the future, a double-blind randomized controlled study must be performed to clarify the role of rivastigmine in promoting functional recovery and improving cognition in patients with AD plus CVD for a long-term period.</s></p></sec><sec sec-type='conclusions' id='sec1_5'><title>Conclusion</title><p><s sid='96'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1>In this multicenter, open-label, 24-week observational study, the rivastigmine patch led to improvements in the K-MBI scores in patients with AD plus CVD.</s></p></sec><sec id='sec1_6'><title>Disclosure Statement</title><p>There are no conflicts of interest.</p></sec></body><back><ack><title>Acknowledgement</title><p>There are no conflicts of interest.</p></ack><ref-list><title>References</title><ref id='B1'><label>1</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Alva</surname><given-names>G</given-names></name><name><surname>Grossberg</surname><given-names>GT</given-names></name><name><surname>Schmitt</surname><given-names>FA</given-names></name><name><surname>Meng</surname><given-names>X</given-names></name><name><surname>Olin</surname><given-names>JT</given-names></name></person-group><article-title>Efficacy of rivastigmine transdermal patch on activities of daily living: item responder analyses</article-title><source>Int J Geriatr Psychiatry</source><year>2011</year><volume>26</volume><fpage>356</fpage><lpage>363</lpage><pub-id pub-id-type='pmid'>21312297</pub-id></element-citation></ref><ref id='B2'><label>2</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Cummings</surname><given-names>JL</given-names></name><name><surname>Koumaras</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Mirski</surname><given-names>D</given-names></name></person-group><article-title>Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer's disease: a 26-week, multicenter, open-label study</article-title><source>Am J Geriatr Pharmacother</source><year>2005</year><volume>3</volume><fpage>137</fpage><lpage>148</lpage><pub-id pub-id-type='pmid'>16257816</pub-id></element-citation></ref><ref id='B3'><label>3</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Grossberg</surname><given-names>G</given-names></name><name><surname>Meng</surname><given-names>X</given-names></name><name><surname>Olin</surname><given-names>JT</given-names></name></person-group><article-title>Impact of rivastigmine patch and capsules on activities of daily living in Alzheimer's disease</article-title><source>Am J Alzheimers Dis Other Demen</source><year>2011</year><volume>26</volume><fpage>65</fpage><lpage>71</lpage><pub-id pub-id-type='pmid'>21282280</pub-id></element-citation></ref><ref id='B4'><label>4</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Jellinger</surname><given-names>KA</given-names></name></person-group><article-title>The enigma of mixed dementia</article-title><source>Alzheimers Dement</source><year>2007</year><volume>3</volume><fpage>40</fpage><lpage>53</lpage><pub-id pub-id-type='pmid'>19595916</pub-id></element-citation></ref><ref id='B5'><label>5</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Erkinjuntti</surname><given-names>T</given-names></name><name><surname>Gauthier</surname><given-names>S</given-names></name><name><surname>Bullock</surname><given-names>R</given-names></name><name><surname>Kurz</surname><given-names>A</given-names></name><name><surname>Hammond</surname><given-names>G</given-names></name><name><surname>Schwalen</surname><given-names>S</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Brashear</surname><given-names>R</given-names></name></person-group><article-title>Galantamine treatment in Alzheimer's disease with cerebrovascular disease: responder analyses from a randomized, controlled trial (GAL-INT-6)</article-title><source>J Psychopharmacol</source><year>2008</year><volume>22</volume><fpage>761</fpage><lpage>768</lpage><pub-id pub-id-type='pmid'>18308781</pub-id></element-citation></ref><ref id='B6'><label>6</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Andersen</surname><given-names>CK</given-names></name><name><surname>Wittrup-Jensen</surname><given-names>KU</given-names></name><name><surname>Lolk</surname><given-names>A</given-names></name><name><surname>Andersen</surname><given-names>K</given-names></name><name><surname>Kragh-Sorensen</surname><given-names>P</given-names></name></person-group><article-title>Ability to perform activities of daily living is the main factor affecting quality of life in patients with dementia</article-title><source>Health Qual Life Outcomes</source><year>2004</year><volume>2</volume><fpage>52</fpage><pub-id pub-id-type='pmid'>15383148</pub-id></element-citation></ref><ref id='B7'><label>7</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Bullock</surname><given-names>R</given-names></name><name><surname>Erkinjuntti</surname><given-names>T</given-names></name><name><surname>Lilienfeld</surname><given-names>S</given-names></name></person-group><article-title>Management of patients with Alzheimer's disease plus cerebrovascular disease: 12-month treatment with galantamine</article-title><source>Dement Geriatr Cogn Disord</source><year>2004</year><volume>17</volume><fpage>29</fpage><lpage>34</lpage><pub-id pub-id-type='pmid'>14560062</pub-id></element-citation></ref><ref id='B8'><label>8</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Small</surname><given-names>G</given-names></name><name><surname>Erkinjuntti</surname><given-names>T</given-names></name><name><surname>Kurz</surname><given-names>A</given-names></name><name><surname>Lilienfeld</surname><given-names>S</given-names></name></person-group><article-title>Galantamine in the treatment of cognitive decline in patients with vascular dementia or Alzheimer's disease with cerebrovascular disease</article-title><source>CNS Drugs</source><year>2003</year><volume>17</volume><fpage>905</fpage><lpage>914</lpage><pub-id pub-id-type='pmid'>12962529</pub-id></element-citation></ref><ref id='B9'><label>9</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Moretti</surname><given-names>R</given-names></name><name><surname>Torre</surname><given-names>P</given-names></name><name><surname>Antonello</surname><given-names>RM</given-names></name><name><surname>Cazzato</surname><given-names>G</given-names></name><name><surname>Bava</surname><given-names>A</given-names></name></person-group><article-title>Rivastigmine in subcortical vascular dementia: an open 22-month study</article-title><source>J Neurol Sci</source><year>2002</year><volume>203-204</volume><fpage>141</fpage><lpage>146</lpage><pub-id pub-id-type='pmid'>12417373</pub-id></element-citation></ref><ref id='B10'><label>10</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Vincent</surname><given-names>S</given-names></name><name><surname>Lane</surname><given-names>R</given-names></name></person-group><article-title>Rivastigmine in vascular dementia</article-title><source>Int Psychogeriatr</source><year>2003</year><volume>15</volume><issue>suppl 1</issue><fpage>201</fpage><lpage>205</lpage><pub-id pub-id-type='pmid'>16191241</pub-id></element-citation></ref><ref id='B11'><label>11</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Farlow</surname><given-names>MR</given-names></name><name><surname>Lilly</surname><given-names>ML</given-names></name></person-group><article-title>Rivastigmine: an open-label, observational study of safety and effectiveness in treating patients with Alzheimer's disease for up to 5 years</article-title><source>BMC Geriatr</source><year>2005</year><volume>5</volume><fpage>3</fpage><pub-id pub-id-type='pmid'>15659242</pub-id></element-citation></ref><ref id='B12'><label>12</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Kumar</surname><given-names>V</given-names></name><name><surname>Anand</surname><given-names>R</given-names></name><name><surname>Messina</surname><given-names>J</given-names></name><name><surname>Hartman</surname><given-names>R</given-names></name><name><surname>Veach</surname><given-names>J</given-names></name></person-group><article-title>An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors</article-title><source>Eur J Neurol</source><year>2000</year><volume>7</volume><fpage>159</fpage><lpage>169</lpage><pub-id pub-id-type='pmid'>10809936</pub-id></element-citation></ref><ref id='B13'><label>13</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Ylikoski</surname><given-names>R</given-names></name><name><surname>Jokinen</surname><given-names>H</given-names></name><name><surname>Andersen</surname><given-names>P</given-names></name><name><surname>Salonen</surname><given-names>O</given-names></name><name><surname>Madureira</surname><given-names>S</given-names></name><name><surname>Ferro</surname><given-names>J</given-names></name><name><surname>Barkhof</surname><given-names>F</given-names></name><name><surname>van der Flier</surname><given-names>W</given-names></name><name><surname>Schmidt</surname><given-names>R</given-names></name><name><surname>Fazekas</surname><given-names>F</given-names></name><etal></etal></person-group><article-title>Comparison of the Alzheimer's Disease Assessment Scale Cognitive Subscale and the Vascular Dementia Assessment Scale in differentiating elderly individuals with different degrees of white matter changes. The LADIS Study</article-title><source>Dement Geriatr Cogn Disord</source><year>2007</year><volume>24</volume><fpage>73</fpage><lpage>81</lpage><pub-id pub-id-type='pmid'>17565216</pub-id></element-citation></ref><ref id='B14'><label>14</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>McKhann</surname><given-names>G</given-names></name><name><surname>Drachman</surname><given-names>D</given-names></name><name><surname>Folstein</surname><given-names>M</given-names></name><name><surname>Katzman</surname><given-names>R</given-names></name><name><surname>Price</surname><given-names>D</given-names></name><name><surname>Stadlan</surname><given-names>EM</given-names></name></person-group><article-title>Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease</article-title><source>Neurology</source><year>1984</year><volume>34</volume><fpage>939</fpage><lpage>944</lpage><pub-id pub-id-type='pmid'>6610841</pub-id></element-citation></ref><ref id='B15'><label>15</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Kurz</surname><given-names>X</given-names></name><name><surname>Scuvee-Moreau</surname><given-names>J</given-names></name><name><surname>Rive</surname><given-names>B</given-names></name><name><surname>Dresse</surname><given-names>A</given-names></name></person-group><article-title>A new approach to the qualitative evaluation of functional disability in dementia</article-title><source>Int J Geriatr Psychiatry</source><year>2003</year><volume>18</volume><fpage>1050</fpage><lpage>1055</lpage><pub-id pub-id-type='pmid'>14618558</pub-id></element-citation></ref><ref id='B16'><label>16</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Galasko</surname><given-names>D</given-names></name><name><surname>Bennett</surname><given-names>D</given-names></name><name><surname>Sano</surname><given-names>M</given-names></name><name><surname>Ernesto</surname><given-names>C</given-names></name><name><surname>Thomas</surname><given-names>R</given-names></name><name><surname>Grundman</surname><given-names>M</given-names></name><name><surname>Ferris</surname><given-names>S</given-names></name></person-group><article-title>An inventory to assess activities of daily living for clinical trials in Alzheimer's disease</article-title><source>The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord</source><year>1997</year><volume>11</volume><issue>suppl 2</issue><fpage>S33</fpage><lpage>S39</lpage></element-citation></ref><ref id='B17'><label>17</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Articus</surname><given-names>K</given-names></name><name><surname>Baier</surname><given-names>M</given-names></name><name><surname>Tracik</surname><given-names>F</given-names></name><name><surname>Kühn</surname><given-names>F</given-names></name><name><surname>Preuss</surname><given-names>UW</given-names></name><name><surname>Kurz</surname><given-names>A</given-names></name></person-group><article-title>A 24-week, multicentre, open evaluation of the clinical effectiveness of the rivastigmine patch in patients with probable Alzheimer's disease</article-title><source>Int J Clin Pract</source><year>2011</year><volume>65</volume><fpage>790</fpage><lpage>796</lpage><pub-id pub-id-type='pmid'>21645184</pub-id></element-citation></ref><ref id='B18'><label>18</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Paolucci</surname><given-names>S</given-names></name><name><surname>Bureca</surname><given-names>I</given-names></name><name><surname>Multari</surname><given-names>M</given-names></name><name><surname>Nocentini</surname><given-names>U</given-names></name><name><surname>Matano</surname><given-names>A</given-names></name></person-group><article-title>An open-label pilot study of the use of rivastigmine to promote functional recovery in patients with unilateral spatial neglect due to first ischemic stroke</article-title><source>Funct Neurol</source><year>2010</year><volume>25</volume><fpage>195</fpage><lpage>200</lpage><pub-id pub-id-type='pmid'>21388579</pub-id></element-citation></ref><ref id='B19'><label>19</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Bullock</surname><given-names>R</given-names></name><name><surname>Touchon</surname><given-names>J</given-names></name><name><surname>Bergman</surname><given-names>H</given-names></name><name><surname>Gambina</surname><given-names>G</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Rapatz</surname><given-names>G</given-names></name><name><surname>Nagel</surname><given-names>J</given-names></name><name><surname>Lane</surname><given-names>R</given-names></name></person-group><article-title>Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period</article-title><source>Curr Med Res Opin</source><year>2005</year><volume>21</volume><fpage>1317</fpage><lpage>1327</lpage><pub-id pub-id-type='pmid'>16083542</pub-id></element-citation></ref><ref id='B20'><label>20</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Small</surname><given-names>GW</given-names></name><name><surname>Kaufer</surname><given-names>D</given-names></name><name><surname>Mendiondo</surname><given-names>MS</given-names></name><name><surname>Quarg</surname><given-names>P</given-names></name><name><surname>Spiegel</surname><given-names>R</given-names></name></person-group><article-title>Cognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 years</article-title><source>Int J Clin Pract</source><year>2005</year><volume>59</volume><fpage>473</fpage><lpage>477</lpage><pub-id pub-id-type='pmid'>15853867</pub-id></element-citation></ref><ref id='B21'><label>21</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Aisen</surname><given-names>PS</given-names></name><name><surname>Schafer</surname><given-names>KA</given-names></name><name><surname>Grundman</surname><given-names>M</given-names></name><name><surname>Pfeiffer</surname><given-names>E</given-names></name><name><surname>Sano</surname><given-names>M</given-names></name><name><surname>Davis</surname><given-names>KL</given-names></name><name><surname>Farlow</surname><given-names>MR</given-names></name><name><surname>Jin</surname><given-names>S</given-names></name><name><surname>Thomas</surname><given-names>RG</given-names></name><name><surname>Thal</surname><given-names>LJ</given-names></name></person-group><article-title>Effects of rofecoxib or naproxen versus placebo on Alzheimer disease progression: a randomized controlled trial</article-title><source>JAMA</source><year>2003</year><volume>289</volume><fpage>2819</fpage><lpage>2826</lpage><pub-id pub-id-type='pmid'>12783912</pub-id></element-citation></ref><ref id='B22'><label>22</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Winblad</surname><given-names>B</given-names></name><name><surname>Kawata</surname><given-names>AK</given-names></name><name><surname>Beusterien</surname><given-names>KM</given-names></name><name><surname>Thomas</surname><given-names>SK</given-names></name><name><surname>Wimo</surname><given-names>A</given-names></name><name><surname>Lane</surname><given-names>R</given-names></name><name><surname>Fillit</surname><given-names>H</given-names></name><name><surname>Blesa</surname><given-names>R</given-names></name></person-group><article-title>Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease</article-title><source>Int J Geriatr Psychiatry</source><year>2007</year><volume>22</volume><fpage>485</fpage><lpage>491</lpage><pub-id pub-id-type='pmid'>17407176</pub-id></element-citation></ref></ref-list></back><floats-group><fig orientation='portrait' id='F1' position='float'><label>Fig. 1</label><caption><p><bold>a</bold> K-MBI. The baseline average K-MBI score was 30.3. A mean improvement of 21.9 was observed as compared with the baseline K-MBI score (* p &lt; 0.05). <bold>b</bold> Subscales of the K-MBI. There was a moderate improvement in several subscale scores of the K-MBI, such as feeding, dressing, toileting, transfer, gait, bladder control and bowel control.</p></caption><graphic xlink:href='dee-0004-0395-g01'></graphic></fig><fig orientation='portrait' id='F2' position='float'><label>Fig. 2</label><caption><p>K-MMSE. The baseline average K-MMSE score was 16.2. A mean improvement of 3.7 was observed as compared with the baseline MMSE score (* p &lt; 0.05).</p></caption><graphic xlink:href='dee-0004-0395-g02'></graphic></fig><fig orientation='portrait' id='F3' position='float'><label>Fig. 3</label><caption><p>Backward digit span score. The baseline average score of the backward digit span test was 0.8. A mean improvement of 0.9 was observed as compared with the baseline score (* p &lt; 0.05).</p></caption><graphic xlink:href='dee-0004-0395-g03'></graphic></fig><table-wrap orientation='portrait' id='T1' position='float'><label>Table 1</label><caption><p>Characteristics of the subjects</p></caption><table rules='groups' frame='hsides'><tbody><tr><td colspan='1' rowspan='1' align='left'>Age, years</td><td colspan='1' rowspan='1' char='.' align='char'>62.8 ± 11.4</td></tr><tr><td colspan='1' rowspan='1' align='left'>Sex (female:male)</td><td colspan='1' rowspan='1' char='.' align='char'>13:16</td></tr><tr><td colspan='1' rowspan='1' align='left'>Diagnosis, n</td><td colspan='1' rowspan='1' char='.' align='char'>29</td></tr><tr><td colspan='1' rowspan='1' align='left'>Cerebral infarction, n</td><td colspan='1' rowspan='1' char='.' align='char'>14</td></tr><tr><td colspan='1' rowspan='1' align='left'>Intracranial hemorrhage, n</td><td colspan='1' rowspan='1' char='.' align='char'>14</td></tr><tr><td colspan='1' rowspan='1' align='left'>Hypoxic brain injury, n</td><td colspan='1' rowspan='1' char='.' align='char'>1</td></tr></tbody></table></table-wrap></floats-group></article></PAPER>